Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast
07 November 2023 - 1:00PM
Business Wire
Event to be webcast live on Wednesday, November
15 at 8:00 a.m. ET
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq:
RPTX), a leading clinical-stage precision oncology company, today
announced it will host a conference call and live webcast to
present the latest data from its ongoing preclinical programs,
RP-1664 and RP-3467, a newly designated Polθ inhibitor, on
Wednesday, November 15, 2023 at 8:00 a.m. Eastern Time.
Conference Call and Webcast Details:
To access the call, please dial (877) 870-4263 (U.S. and Canada)
or (412) 317-0790 (international) at least 10 minutes prior to the
start time and ask to be joined to the Repare Therapeutics call. A
live webcast will be available in the Investor section of the
Company’s website at
https://ir.reparerx.com/events-and-presentations/events. A webcast
replay will also be archived for at least 30 days.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision
oncology company enabled by its proprietary synthetic lethality
approach to the discovery and development of novel therapeutics.
The Company utilizes its genome-wide, CRISPR-enabled SNIPRx®
platform to systematically discover and develop highly targeted
cancer therapies focused on genomic instability, including DNA
damage repair. The Company’s pipeline includes lunresertib (also
known as RP-6306), a PKMYT1 inhibitor currently in Phase 1 clinical
development; camonsertib (also known as RP-3500 or RG6526), a
potential leading ATR inhibitor currently in Phase 1/2 clinical
development and partnered with Roche; RP-3467, a preclinical Polθ
inhibitor program; as well as several additional, undisclosed
preclinical programs, including RP-1664. For more information,
please visit reparerx.com and follow @Reparerx on X (formerly
Twitter) and LinkedIn.
SNIPRx® is a registered trademark of Repare Therapeutics
Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231107600865/en/
Repare: Steve Forte Executive Vice-President and Chief
Financial Officer Repare Therapeutics Inc.
investor@reparerx.com
Investors: Matthew DeYoung Argot Partners
repare@argotpartners.com
Media: David Rosen Argot Partners
david.rosen@argotpartners.com 212-600-1902
Repare Therapeutics (NASDAQ:RPTX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Repare Therapeutics (NASDAQ:RPTX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024